The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Rapamycin is the most intellectually compelling longevity compound in this book and the one with the greatest evidence-to-certainty gap. The biology is as strong as any longevity intervention has ever been. The human longevity data is 48 weeks old and based on a small trial.
The honest summary: the preclinical case for rapamycin as a longevity intervention is uniquely robust — ITP mouse data, independently replicated, dose-dependent, effective even when started late in life. The mechanism (mTOR inhibition restoring autophagy and reducing age-related cellular dysfunction) is intellectually coherent and conserved across species. The human safety data at weekly intermittent doses is encouraging — PEARL showed adverse events comparable to placebo over 48 weeks, with lean mass benefit in women at ~3.3 mg/week commercial equivalent exposure. The Mannick studies showed immune enhancement (not suppression) with intermittent rapalog dosing. But: the optimal human dose is unknown; the longevity effect in humans is unproven; the drug interaction profile makes it genuinely dangerous to use without physician oversight; the immunosuppression risk at higher doses is real; and the bioavailability of compounded rapamycin is substantially lower than pharmaceutical Rapamune, making dose comparisons unreliable. For the community user: rapamycin at weekly doses under physician supervision with monitoring is the only appropriate context for longevity use. It is not a compound to start based on a Reddit protocol alone.
Rapamycin was discovered in a soil sample from Easter Island (Rapa Nui) in 1972. It took 37 years to discover that it extends mammalian lifespan. It may be another 20 years before we know whether it extends human healthspan. Everything in between is the most interesting story in geroscience.
The bacterium Streptomyces hygroscopicus, isolated from Easter Island soil by Suren Sehgal at Ayerst Research Laboratories, produced a compound with remarkable antifungal activity. The compound — named rapamycin after its island of origin — was initially developed as an antifungal. Its immunosuppressive properties were subsequently discovered: rapamycin prevented organ rejection in transplant models. In 1999, sirolimus (rapamycin) received FDA approval as an immunosuppressant for kidney transplant recipients. The mechanism: rapamycin binds FKBP12, and the rapamycin-FKBP12 complex inhibits mTOR (mechanistic target of rapamycin, originally named after its bacterial inhibitor). mTOR is a serine/threonine kinase that serves as a master regulator of cell growth, protein synthesis, autophagy, and metabolic sensing — at the intersection of nutrient availability, energy status, and cellular fate decisions.
The longevity connection emerged from aging research: mTOR activity increases with age in multiple tissues; caloric restriction — the most reproducible lifespan-extending intervention across species — works in part by reducing mTOR activity. If mTOR hyperactivity is a driver of aging, could mTOR inhibition pharmacologically replicate caloric restriction's longevity effects? The NIA Interventions Testing Program (ITP) provided the decisive preclinical answer in 2009: Harrison [1] et al. reported in Nature that rapamycin extended the lifespan of genetically heterogeneous mice when started at 600 days of age — an age equivalent to approximately 60 human years. This was the first demonstration that a pharmacological intervention started late in life could meaningfully extend mammalian lifespan. Reproduced at three independent sites. Reproduced at multiple doses. Reproduced in multiple subsequent studies. Rapamycin became the most important longevity compound in preclinical geroscience.
THE CENTRAL TENSION
Rapamycin is the most evidence-supported longevity compound in mammalian biology — full stop. The ITP lifespan extension data is uniquely robust: independently replicated, dose-dependent, consistent across sexes, effective even when started late in life. The mechanism (mTOR inhibition reducing the hyperactive mTOR signaling that characterizes aged tissue) is intellectually coherent and consistent with the caloric restriction literature. The PEARL trial (April 2025) provides the first 48-week placebo-controlled human longevity data and shows a favorable safety profile at weekly low doses with measurable lean mass benefit in women. And yet: the transplant medicine literature is dominated by immunosuppression complications, serious infections, impaired wound healing, metabolic effects (hyperglycemia, dyslipidemia), and ulcers — all from continuous daily dosing. The longevity community's key hypothesis is that intermittent weekly dosing produces enough mTOR inhibition for longevity benefit while avoiding the steady-state immunosuppression of continuous dosing. This hypothesis is pharmacologically plausible and supported by the PEARL safety data — but the optimal dose, the duration, the long-term safety at intermittent doses, and the actual longevity effect in humans remain unknown.
The most common error in rapamycin safety discussions is applying continuous daily transplant dosing adverse effects directly to once-weekly longevity dosing. The pharmacologies are not equivalent.
At 2-5 mg/day continuous transplant dosing: oral mucositis and stomatitis (mouth sores) — the most common complaint at transplant doses; hyperlipidemia — LDL and triglyceride increases; hyperglycemia and insulin resistance — dose-dependent; impaired wound healing — significant surgical concern; immunosuppression — increased risk of opportunistic infections, HSV reactivation, CMV, pneumocystis; interstitial pneumonitis (rare but serious); edema; thrombocytopenia; anemia. These adverse effects are well-documented in the transplant literature and are the reason rapamycin has historically been viewed as too dangerous for general longevity use.
At 5-10 mg/week compounded (effective ~1.7-3.3 mg/week commercial equivalent): the PEARL trial found adverse events comparable to placebo over 48 weeks; mild GI discomfort was the most common reported effect; no significant immunosuppression signal; no significant metabolic disruption (glucose, lipids) at this dose range; lean tissue mass improved significantly in women on 10 mg/week compounded. The AgelessRx observational study of 333 low-dose rapamycin users showed similar favorable profiles. The Mannick immune data showed immune function improvement. This favorable profile is consistent with the intermittent dosing hypothesis: the weekly pulse produces biological effects without sustaining the steady-state immunosuppression of continuous dosing. However: the PEARL trial was 48 weeks; the bioavailability issue means effective doses were quite low; and long-term safety data beyond 1-2 years is not available.
Even at weekly dosing, rapamycin produces some immune effects. The key clinical concerns: infection risk increases at higher doses and more frequent dosing; any active infection, dental procedure, or surgery represents a period where rapamycin should be paused; live vaccines should not be administered during rapamycin use; annual or biannual CBC (complete blood count) and comprehensive metabolic panel monitoring is appropriate; anyone who develops signs of unusual infection (prolonged illness, fever, opportunistic pathogen pattern) should pause rapamycin and evaluate. The infection risk at weekly dosing is substantially lower than at continuous transplant dosing — but it is not zero, particularly in immunocompromised individuals.
mTOR inhibition reduces insulin sensitivity — a dose-dependent effect. At weekly low doses, the PEARL trial showed no significant glucose disruption. At higher doses or in pre-diabetic individuals, glucose elevation is possible. Fasting glucose and HbA1c at baseline and annually during rapamycin use is appropriate monitoring. T2D patients or insulin-dependent individuals should not use rapamycin without endocrinologist oversight.
Rapamycin impairs wound healing by inhibiting mTOR-dependent cellular proliferation and collagen synthesis required for wound repair. This is most relevant at continuous transplant doses. At weekly intermittent doses, the concern is lower but not absent. Practical guidance: pause rapamycin 1-2 weeks before any elective surgical procedure; resume after wound closure is confirmed; do not use rapamycin if wounds are actively present.
ACTIVE INFECTION — PAUSE RAPAMYCIN
Any active infection — bacterial, viral, or fungal — is a reason to pause rapamycin immediately. mTOR inhibition impairs the proliferative immune response required to control active infection. This is especially relevant for: dental infections; respiratory infections; urinary tract infections; any condition requiring antibiotic treatment. Resume rapamycin only after infection has fully resolved. The interaction with azole antifungals (fluconazole, itraconazole) is particularly dangerous — these are CYP3A4 inhibitors that can raise rapamycin levels 5-20x, potentially producing transplant-level immunosuppression from a longevity dose.
mTOR (mechanistic Target Of Rapamycin) is a serine/threonine protein kinase that exists in two distinct complexes: mTORC1 (mTOR Complex 1) and mTORC2 (mTOR Complex 2). They have different substrates, different regulators, and different sensitivity to rapamycin. mTORC1: primary target of rapamycin at standard dosing; contains raptor; activates protein synthesis (via S6K1 phosphorylation and 4E-BP1 phosphorylation); inhibits autophagy; responds to nutrients, growth factors, energy status. mTORC2: contains rictor; regulates cytoskeletal organization; activates Akt; more resistant to acute rapamycin but sensitive to prolonged/continuous dosing — the complex implicated in immunosuppression. The aging relevance of mTORC1: mTORC1 activity increases with age in multiple tissues — muscle, brain, liver, immune cells. This age-associated mTOR hyperactivity: suppresses autophagy (reducing cellular housekeeping and damaged protein/organelle clearance); drives senescent cell secretory phenotype; impairs stem cell function; promotes cellular senescence. Partial mTORC1 inhibition restores autophagy, reduces cellular senescence markers, and improves stem cell function in aged tissues.
The most important mechanistic link between mTOR inhibition and longevity is autophagy — the cellular self-cleaning process that degrades damaged proteins, dysfunctional organelles, and aggregated molecules. Autophagy declines with age in most tissues; this decline correlates with and contributes to the cellular dysfunction characteristic of aging. mTORC1 is the master negative regulator of autophagy — when nutrients and growth factors are abundant, mTORC1 is active and autophagy is suppressed. When mTORC1 is inhibited (caloric restriction, rapamycin), autophagy is de-repressed. The rapamycin longevity hypothesis in brief: partial mTOR inhibition → autophagy restoration → reduced cellular burden of damaged components → improved cellular and tissue function → reduced age-related disease → extended healthspan and lifespan.
The distinction between intermittent (once-weekly) and continuous (daily transplant protocol) dosing is the most important pharmacological concept for the community use of rapamycin. At continuous daily dosing (2-5 mg/day; transplant): mTOR remains continuously inhibited; mTORC2 is eventually inhibited (contributing to immunosuppression); steady-state trough levels maintained; maximal immunosuppression and metabolic effects. At intermittent weekly dosing (5-6 mg/week): peak rapamycin levels at 12-24 hours post-dose; substantial recovery toward baseline over days 3-7; mTOR inhibition is pulsatile rather than continuous; mTORC2 inhibition is reduced relative to continuous dosing; the hypothesis is that the pulsatile mTORC1 inhibition is sufficient to activate autophagy and other longevity-relevant pathways during the peak period, while the recovery phase between doses allows immune function to normalize. This intermittent paradigm was supported by the Mannick et al. 2018 [3] Science Translational Medicine study showing that 5 mg/week of a rapalog for 6 weeks in elderly adults actually improved immune function (enhanced vaccine response) — the opposite of the immunosuppression seen with continuous dosing.
The PEARL trial (April 2025) identified a critical pharmacological finding that most community protocols have not yet fully incorporated: compounded rapamycin preparations are approximately 66% less bioavailable than commercial pharmaceutical-grade sirolimus (Rapamune). This means that community users taking 6 mg/week of compounded rapamycin are receiving an effective systemic exposure equivalent to approximately 2 mg/week of commercial Rapamune. The PEARL trial saw meaningful biological effects (lean tissue mass improvement in women) at this effective dose of ~1.7-3.3 mg/week commercial-equivalent. The implications: (1) compounded rapamycin at community doses is less potent than assumed; (2) the lack of serious immunosuppression in community users may partly reflect this lower-than-labeled effective dose; (3) dose comparisons between studies using compounded vs pharmaceutical rapamycin require formulation-specific bioavailability data.
Rapamycin has the strongest preclinical longevity evidence base of any compound in this book. The human evidence is now accumulating but remains early.
Harrison DE, Strong R, Sharp ZD, et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 460(7253):392-395. Design: genetically heterogeneous (UM-HET3) mice; rapamycin encapsulated in enteric-coated food (administered at 600 days of age, equivalent to ~60 human years); three independent NIA ITP sites (University of Michigan, University of Texas, Jackson Laboratory). Results: median lifespan extended ~9% in males, ~14% in females across all three sites simultaneously. This simultaneous triple-site replication is the gold standard of preclinical longevity data. Subsequent ITP studies: rapamycin starting at 270 days (earlier age) produced larger lifespan extension; dose-response studies confirmed effect at multiple doses; effects in diverse mouse backgrounds. Non-mouse data: marmoset studies (Tardif et al.) showing health improvements; Interventions Testing Program dog studies (Dog Aging Project) showing cardiac improvements in older large dogs. Grade B: robust, multiply-replicated animal data from the most rigorous preclinical longevity testing program in existence; non-human primate data encouraging; human translation uncertain.
Mannick JB, Del Giudice G, Lattanzi M, et al. (2014) [2]. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 6(268):268ra179. A rapalog (RAD001/everolimus; an mTOR inhibitor similar to rapamycin) at 0.5 mg/day or 5 mg/week for 6 weeks in elderly volunteers: significantly improved influenza vaccine response (enhanced antibody titers); reduced percentage of immunosuppressive T regulatory cells. The counterintuitive result: intermittent mTOR inhibition improves immune function in the elderly rather than suppressing it. This finding is one of the most important human longevity pharmacology results published and provides mechanistic support for the intermittent dosing hypothesis.
Moel M, Harinath G, Lee V, et al. (2025) [4]. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Aging-US). 17(4). NCT04488601. Published April 4, 2025. Design: 48-week decentralized double-blinded RCT; healthy normative-aging adults; compounded rapamycin 5 mg/week or 10 mg/week vs placebo. Primary endpoint: visceral adiposity reduction by DXA (not statistically met). Secondary findings: lean tissue mass significantly increased in women on 10 mg/week; self-reported pain improved in women; safety profile comparable to placebo; most common adverse effect was mild GI discomfort. CRITICAL BIOAVAILABILITY FINDING: compounded rapamycin was ~66% less bioavailable than commercial Rapamune — effective doses were ~1.7 mg/week and ~3.3 mg/week of commercial equivalent. The 10 mg/week compounded dose = ~3.3 mg/week commercial = a pharmacologically modest dose. The PEARL trial is the most important published human longevity data for rapamycin as of mid-2026.
As of mid-2026, the largest human rapamycin longevity trial yet conducted is underway — n=720 participants; 2-year weekly dosing; primary outcome safety and trough level characterization; biological response patterns at scale. This trial will generate the first large-sample long-term pharmacokinetic and safety dataset for weekly rapamycin in non-transplant populations. Results are not yet available.
Several smaller 2025 human studies added to the rapamycin evidence base: IVF trial showing short-term low-dose rapamycin improved embryo quality and clinical pregnancy rates, with evidence of reversed ovarian aging molecular signatures (ribosomal dysregulation and suppressed autophagy reversed); chronic fatigue syndrome pilot showing restored autophagy and improvements in fatigue and post-exertional malaise; cardiac dysfunction pilot in older men showing improved cardiac and endothelial function. These are small, non-longevity endpoint studies — but they demonstrate mechanistic effects of rapamycin in humans consistent with mTOR inhibition biology.
Evidence
Grade
Key Finding
Limitation
ITP mouse lifespan (Harrison 2009, Nature)
B (animal)
~14% female, ~9% male median lifespan extension started late in life; triple-site replication; dose-dependent
Animal data; human translation uncertain
Mannick 2014 (Sci Transl Med)
B (human)
Rapalog improved vaccine response and immune function in elderly; intermittent dosing enhances immunity
Small n; short duration; rapalog not identical to rapamycin
PEARL trial 2025 (Aging-US)
B (human RCT)
48 weeks safe in healthy adults; lean mass improved in women on 10 mg/week compounded; adverse events comparable to placebo
Primary endpoint not met; compounded formulation 66% less bioavailable; small trial; women-specific lean mass finding
Ongoing large trial 2026
Pending
n=720; 2-year weekly; safety and PK primary
No results yet; in progress
2025 IVF / CFS / cardiac pilots
C (small human)
Mechanistic mTOR effects; autophagy restored; functional improvements
Small n; non-aging-endpoint studies; suggestive not definitive
The community longevity protocol for rapamycin is built on the ITP data, the Mannick immune enhancement finding, and the pharmacological argument for intermittent vs continuous dosing.
Community longevity users typically follow protocols derived from physician-longevity-prescribers (notably Dr. Alan Green, who has prescribed rapamycin for longevity since the 2010s and maintains a community-shared database of outcomes). Standard protocol: 5-10 mg compounded rapamycin once weekly; pharmaceutical Rapamune equivalent ~1.7-3.3 mg/week based on PEARL bioavailability data; taken on an empty stomach or with a fat-containing meal (fat increases absorption); cycled on/off by some practitioners (typically 6 months on / 2 months off; or continuous with monitoring). Starting dose typically lower: 1-2 mg/week pharmaceutical or 3-5 mg/week compounded, titrated up over weeks based on tolerance.
Context
Dose (Compounded)
Dose (Commercial Rapamune Equivalent)
Notes
Conservative start
3-5 mg once weekly
~1-1.7 mg/week equivalent
Lower dose for first use; assess tolerance; many users report no side effects
Standard community protocol
5-6 mg once weekly
~1.7-2 mg/week equivalent
Most commonly reported dose; aligns with Mannick 5 mg/week rapalog protocol
PEARL trial high dose
10 mg once weekly
~3.3 mg/week equivalent
Showed lean mass benefit in women; primary endpoint not met; adverse events comparable to placebo
Physician-prescribed range
5-20 mg once weekly compounded
~1.7-6.7 mg/week equivalent
Some longevity physicians prescribe up to 20 mg/week compounded; higher doses less studied
Rapamycin has the most dangerous drug interaction profile of any compound in this book. CYP3A4 interactions can convert a longevity dose into a transplant-level immunosuppressant without any change in the rapamycin dose itself.
Interacting Drug/Class
Effect on Rapamycin
Clinical Risk
Action
Azole antifungals (fluconazole, itraconazole, voriconazole, ketoconazole)
CYP3A4 inhibition → rapamycin levels ↑ 5-20x
SEVERE — a routine yeast infection prescription becomes potentially life-threatening immunosuppression
Stop rapamycin before starting any azole; physician coordination essential
Grapefruit / grapefruit juice
CYP3A4 inhibition → rapamycin absorption ↑ significantly
Unpredictable; can increase exposure 1.5-3x
Avoid all grapefruit during rapamycin use
Clarithromycin / erythromycin
Strong CYP3A4 inhibition → rapamycin ↑ significantly
Antibiotic for common infections; could produce dangerous rapamycin elevation
Avoid; use amoxicillin or azithromycin alternatives when possible
Rifampin / rifampicin
CYP3A4 induction → rapamycin levels ↓ dramatically
Rapamycin becomes ineffective; significant reduction in plasma levels
Avoid or dramatically increase rapamycin dose with monitoring
Carbamazepine, phenytoin, phenobarbital
CYP3A4 induction → rapamycin levels ↓
Significant reduction in rapamycin exposure
Monitor levels if combined; may need dose adjustment
Cyclosporine (used in transplant)
Complex interaction; can increase rapamycin exposure
Transplant context only; both immunosuppressants together require careful TDM
Physician-managed transplant context only
Tacrolimus
Complex interaction — mTOR inhibitor + calcineurin inhibitor
Transplant context; additive immunosuppression
Physician-managed only
NSAIDs (ibuprofen, naproxen)
May increase nephrotoxicity risk (mTOR inhibition + NSAID)
Increased kidney injury risk; especially at higher rapamycin doses
Avoid chronic combined use; acetaminophen preferred
Metformin
Both inhibit mTOR via different pathways; additive mTOR inhibition
Potentially additive benefit for longevity; additive metabolic effects — monitor glucose
May be beneficial combination for longevity; requires monitoring; physician coordination
Test
Timing
What to Look For
Fasting glucose + HbA1c
Baseline; 3 months; every 6 months
mTOR inhibition impairs insulin sensitivity; pre-diabetic/diabetic individuals at higher risk
CBC (complete blood count)
Baseline; 6 months; annually
Thrombocytopenia, leukopenia — rare at weekly doses but baseline important
Comprehensive metabolic panel (CMP)
Baseline; 6 months; annually
Kidney function (BUN/creatinine); liver enzymes; electrolytes
Lipid panel
Baseline; 6 months; annually
mTOR inhibition can increase LDL and triglycerides dose-dependently
Sirolimus trough level
Optional; ideally at 24-48h post-dose (trough) before next weekly dose
Confirms exposure in expected range; identifies poor metabolizers or unexpected interactions; commercial lab available
Vaccination status
Before starting
No live vaccines during rapamycin use; ensure up-to-date on inactivated vaccines before starting
Dental evaluation
Before starting; every 6-12 months
Stomatitis risk; oral health baseline; elective dental work before starting rapamycin
This framing applies to continuous daily transplant dosing. The transplant literature reports serious infection rates and some increased malignancy risk at doses of 2-5 mg/day continuous. At weekly intermittent community doses (5-6 mg/week compounded; ~1.7-2 mg/week commercial equivalent), the PEARL trial showed adverse events comparable to placebo. Mannick et al. showed intermittent rapalog treatment actually IMPROVED immune function in elderly adults (enhanced vaccine response, fewer infections). The immunosuppression risk at intermittent longevity doses is lower than the transplant framing implies — but not zero, and it requires monitoring and management.
mTOR inhibition impairs insulin sensitivity, and continuous transplant dosing produces clinically significant hyperglycemia in a substantial fraction of patients. At weekly intermittent doses in the PEARL trial: no significant glucose disruption was documented. Pre-diabetic individuals and those with insulin resistance are at higher risk and require monitoring. The 'rapamycin causes diabetes' claim is accurate for transplant dosing; it requires qualification for weekly longevity dosing.
The ITP data is the strongest mammalian longevity pharmacology evidence in existence. It does not prove human lifespan extension. Human translation of mouse longevity pharmacology has a historically poor success rate (resveratrol, metformin in mice — neither has demonstrated human longevity in controlled trials). The mechanism (mTOR inhibition) is conserved and biologically coherent. Whether the dose, timing, and duration of weekly rapamycin in humans produces sufficient mTOR inhibition in relevant tissues to reproduce the ITP mouse effect is unknown. PEARL showed biological effects at very low effective doses (~3 mg/week commercial equivalent) — suggesting human sensitivity may be reasonable. But the leap from 'mice live longer' to 'humans will live longer' is not pharmacologically guaranteed.
Transplant medicine rapamycin is a closely monitored, continuous-dosing, therapeutic drug use context with regular trough level measurements, full blood counts, and physician oversight specifically because of the serious adverse effects at those doses. Longevity community use is off-label, without routine monitoring, and at doses that are pharmacologically different from transplant use. The decades of transplant safety data do not validate unmonitored longevity use. The data that validates weekly longevity dosing is the Mannick study, the PEARL trial, and the observational series — not the transplant literature.
Rapalogs are rapamycin derivatives designed with modified pharmacokinetic profiles. The primary rapalogs: everolimus (RAD001; Zortress, Afinitor) — the most studied rapalog; hydroxyl ester prodrug of rapamycin; shorter half-life than rapamycin; FDA-approved for transplant, several cancers; used in Mannick immune aging studies. Temsirolimus (CCI-779; Torisel) — IV formulation; approved for renal cell carcinoma. Ridaforolimus — clinical development stage. The Mannick et al. immune aging studies used RAD001 (everolimus), not rapamycin itself — meaning the human immune function improvement data is technically from a rapalog. However, the mechanism is identical. Rapamycin has a longer half-life (~62 hours) and typically lower bioavailability from oral dosing than everolimus. The community preference for rapamycin over everolimus is primarily driven by cost, availability, and the historical longevity community familiarity with the compound.
Harrison DE, Strong R, Sharp ZD, et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 460:392-395. doi:10.1038/nature08221. [The original ITP triple-site replication; most important longevity pharmacology paper in preclinical geroscience; ~14% female and ~9% male median lifespan extension started at 600-day-old mice.]
Mannick JB, Del Giudice G, Lattanzi M, et al. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 6(268):268ra179. [RAD001/everolimus 0.5 mg/day or 5 mg/week x6 weeks in elderly; significantly improved influenza vaccine response; reduced immunosuppressive T-reg cells; intermittent mTOR inhibition enhances aging immune function.]
Mannick JB, Morris M, Hockey HUP, et al. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine. 10(449):eaaq1564. [RAD001 follow-up study; 5 mg/week; reduced respiratory infections; confirms enhanced immune function with intermittent rapalog in elderly.]
Moel M, Harinath G, Lee V, et al. (2025). Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Aging-US). 17(4). doi:10.18632/aging.206235. NCT04488601. Published April 4, 2025. [48-week DBRCT; compounded rapamycin 5 or 10 mg/week vs placebo; safe profile comparable to placebo; lean tissue mass improved significantly in women on 10 mg/week; primary endpoint not met; compounded formulation 66% less bioavailable — effective doses ~1.7-3.3 mg/week commercial equivalent.]
Rapamycin is the most intellectually compelling longevity compound in this book and the one with the greatest evidence-to-certainty gap. The biology is as strong as any longevity intervention has ever been. The human longevity data is 48 weeks old and based on a small trial.
The honest summary: the preclinical case for rapamycin as a longevity intervention is uniquely robust — ITP mouse data, independently replicated, dose-dependent, effective even when started late in life. The mechanism (mTOR inhibition restoring autophagy and reducing age-related cellular dysfunction) is intellectually coherent and conserved across species. The human safety data at weekly intermittent doses is encouraging — PEARL showed adverse events comparable to placebo over 48 weeks, with lean mass benefit in women at ~3.3 mg/week commercial equivalent exposure. The Mannick studies showed immune enhancement (not suppression) with intermittent rapalog dosing. But: the optimal human dose is unknown; the longevity effect in humans is unproven; the drug interaction profile makes it genuinely dangerous to use without physician oversight; the immunosuppression risk at higher doses is real; and the bioavailability of compounded rapamycin is substantially lower than pharmaceutical Rapamune, making dose comparisons unreliable. For the community user: rapamycin at weekly doses under physician supervision with monitoring is the only appropriate context for longevity use. It is not a compound to start based on a Reddit protocol alone.
Rapamycin is the most intellectually compelling longevity compound in this book and the one with the greatest evidence-to-certainty gap. The biology is as strong as any longevity intervention has ever been. The human longevity data is 48 weeks old and based on a small trial.
The honest summary: the preclinical case for rapamycin as a longevity intervention is uniquely robust — ITP mouse data, independently replicated, dose-dependent, effective even when started late in life. The mechanism (mTOR inhibition restoring autophagy and reducing age-related cellular dysfunction) is intellectually coherent and conserved across species. The human safety data at weekly intermittent doses is encouraging — PEARL showed adverse events comparable to placebo over 48 weeks, with lean mass benefit in women at ~3.3 mg/week commercial equivalent exposure. The Mannick studies showed immune enhancement (not suppression) with intermittent rapalog dosing. But: the optimal human dose is unknown; the longevity effect in humans is unproven; the drug interaction profile makes it genuinely dangerous to use without physician oversight; the immunosuppression risk at higher doses is real; and the bioavailability of compounded rapamycin is substantially lower than pharmaceutical Rapamune, making dose comparisons unreliable. For the community user: rapamycin at weekly doses under physician supervision with monitoring is the only appropriate context for longevity use. It is not a compound to start based on a Reddit protocol alone.
— End of Rapamycin —
THE PEPTIDE BIBLE | Rapamycin | For Research & Educational Purposes Only
Rapamycin (sirolimus): macrolide natural product; Streptomyces hygroscopicus; MW 914 Da; oral; mTOR inhibitor (mTORC1 primary target). FDA-APPROVED: kidney transplant rejection (Rapamune); LAM; SEGA; rapalogs (everolimus/Afinitor) for multiple cancers. Off-label community use: longevity. MECHANISM: binds FKBP12 → FKBP12-rapamycin complex inhibits mTORC1 → S6K1↓, 4E-BP1 phosphorylation↓ (protein synthesis↓) + autophagy de-repression; mTORC2 (rictor; immunosuppressive complex) more resistant to acute rapamycin; continuous dosing eventually inhibits mTORC2. AGING RELEVANCE: mTORC1 hyperactive in aged tissue; inhibition restores autophagy, reduces senescent secretome, improves stem cell function. ITP MOUSE DATA (Harrison 2009, Nature): ~14% female, ~9% male median lifespan extension; started 600-day-old mice (equivalent to ~60 human years); THREE independent laboratory sites simultaneously; dose-dependent; most replicated mammalian longevity pharmacology result in existence. MANNICK 2014/2018: RAD001 (rapalog) 5 mg/week in elderly → improved immune function (enhanced vaccine response); FEWER infections — intermittent dosing enhances aging immunity. PEARL TRIAL (2025; Moel et al., Aging-US; NCT04488601; 48 wks; n=participants; compounded 5 or 10 mg/week): primary endpoint (visceral adiposity) not met; lean tissue mass significantly increased in women on 10 mg/week; adverse events comparable to placebo; CRITICAL: compounded rapamycin ~66% less bioavailable than commercial Rapamune; effective doses ~1.7-3.3 mg/week commercial equivalent. LARGE ONGOING TRIAL: n=720; 2-year weekly dosing; safety/PK primary; no results yet. INTERMITTENT vs CONTINUOUS: weekly pulse = pulsatile mTORC1 inhibition; recovery between doses; reduced mTORC2 inhibition; favorable immune profile. Continuous daily = sustained mTOR inhibition; mTORC2 eventually inhibited; immunosuppression; metabolic effects. SAFETY AT WEEKLY DOSES: PEARL comparable to placebo; mild GI most common. TRANSPLANT DOSES SAFETY: stomatitis; hyperlipidemia; hyperglycemia; impaired wound healing; immunosuppression; interstitial pneumonitis; thrombocytopenia. DRUG INTERACTIONS (CRITICAL): CYP3A4 inhibitors → rapamycin levels 5-20x; azole antifungals (fluconazole etc.) = MAJOR interaction; grapefruit = avoid; erythromycin/clarithromycin = avoid. MONITORING: CBC; CMP; lipid panel; fasting glucose/HbA1c; baseline + q3-6 months; optional trough sirolimus level. CONTRAINDICATIONS: active infection (pause); active malignancy (oncologist required); concurrent azole antifungals; pregnancy; surgery within 2-4 weeks. WADA: not listed (immunosuppressant, not anabolic). No HPTA suppression.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.